We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.
- Authors
Lesterhuis, W. J.; de Vries, I. J. M.; Aarntzen, E. A.; de Boer, A.; Scharenborg, N. M.; van de Rakt, M.; van Spronsen, D.-J.; Preijers, F. W.; Figdor, C. G.; Adema, G. J.; Punt, C. J. A.
- Abstract
<bold>Background: </bold>Dendritic cell (DC) vaccination has been shown to induce anti-tumour immune responses in cancer patients, but so far its clinical efficacy is limited. Recent evidence supports an immunogenic effect of cytotoxic chemotherapy. Pre-clinical data indicate that the combination of chemotherapy and immunotherapy may result in an enhanced anti-cancer activity. Most studies have focused on the immunogenic aspect of chemotherapy-induced cell death, but only few studies have investigated the effect of chemotherapeutic agents on the effector lymphocytes of the immune system.<bold>Methods: </bold>Here we investigated the effect of treatment with oxaliplatin and capecitabine on non-specific and specific DC vaccine-induced adaptive immune responses. Stage III colon cancer patients receiving standard adjuvant oxaliplatin/capecitabine chemotherapy were vaccinated at the same time with keyhole limpet haemocyanin (KLH) and carcinoembryonic antigen (CEA)-peptide pulsed DCs.<bold>Results: </bold>In 4 out of 7 patients, functional CEA-specific T-cell responses were found at delayed type hypersensitivity (DTH) skin testing. In addition, we observed an enhanced non-specific T-cell reactivity upon oxaliplatin administration. KLH-specific T-cell responses remained unaffected by the chemotherapy, whereas B-cell responses were diminished.<bold>Conclusion: </bold>The results strongly support further testing of the combined use of specific anti-tumour vaccination with oxaliplatin-based chemotherapy.
- Subjects
ADJUVANT treatment of cancer; COLON cancer patients; IMMUNOGENETICS; DRUG therapy; ANTIBODY-dependent cell cytotoxicity; ANTINEOPLASTIC agents; LYMPHOID tissue
- Publication
British Journal of Cancer, 2010, Vol 103, Issue 9, p1415
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/sj.bjc.6605935